Lexeo Therapeutics

based in new york city, lexeo therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. building on groundbreaking research from weill cornell medicine and the university of california san diego, lexeo partners with preeminent institutions on the cutting edge of gene therapy research. using a stepwise development approach, lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and apoe4 associated alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. for more information, please visit www.lexeotx.com.